Ascendis Pharma A/S (ASND)
151.17
+2.73
(+1.84%)
USD |
NASDAQ |
Mar 28, 16:00
151.10
-0.07
(-0.05%)
After-Hours: 20:00
Ascendis Pharma Cash from Financing (TTM): 145.39M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 145.39M |
September 30, 2023 | 172.90M |
June 30, 2023 | -6.124M |
March 31, 2023 | -28.62M |
December 31, 2022 | 418.44M |
September 30, 2022 | 375.47M |
June 30, 2022 | 835.33M |
March 31, 2022 | 862.04M |
December 31, 2021 | 415.75M |
September 30, 2021 | 434.19M |
June 30, 2021 | 681.50M |
March 31, 2021 | 689.50M |
December 31, 2020 | 688.24M |
September 30, 2020 | 701.16M |
June 30, 2020 | 13.70M |
March 31, 2020 | 7.156M |
December 31, 2019 | 552.58M |
September 30, 2019 | 548.84M |
June 30, 2019 | 548.22M |
Date | Value |
---|---|
March 31, 2019 | 542.31M |
December 31, 2018 | 240.02M |
September 30, 2018 | 249.21M |
June 30, 2018 | 379.67M |
March 31, 2018 | 382.46M |
December 31, 2017 | 141.25M |
September 30, 2017 | 256.60M |
June 30, 2017 | 130.13M |
March 31, 2017 | 130.69M |
December 31, 2016 | 130.00M |
September 30, 2016 | 0.5416M |
June 30, 2016 | 4.581M |
March 31, 2016 | 2.909M |
December 31, 2015 | 117.34M |
September 30, 2015 | 181.76M |
June 30, 2015 | 177.05M |
March 31, 2015 | 178.14M |
December 31, 2014 | 63.71M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-28.62M
Minimum
Mar 2023
862.04M
Maximum
Mar 2022
429.90M
Average
488.25M
Median
Cash from Financing (TTM) Benchmarks
Evaxion Biotech AS | -- |
Genmab A/S | -87.98M |
Autolus Therapeutics PLC | -0.883M |
Adaptimmune Therapeutics PLC | 0.88M |
argenx SE | -- |